Abstract
It is expected that future treatments will be preceded by genetic tests to prescribe the most effect asthma medication while lowering the risk of adverse side effects. However, it will not be necessary to describe all the genetic determinants affecting drug response to apply pharmacogenomics to asthma therapy. Whether pharmacogenomics becomes common practice may not depend on the availability of tests, but on factors such as affordability, ease of application, and ease of interpreting the results.
Original language | English (US) |
---|---|
Pages (from-to) | 723-742 |
Number of pages | 20 |
Journal | Immunology and Allergy Clinics of North America |
Volume | 25 |
Issue number | 4 |
DOIs | |
State | Published - Nov 2005 |
Externally published | Yes |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology